Cas:120814-48-4 (Pro7)-Neurokinin B manufacturer & supplier

Chemical Name:(Pro7)-Neurokinin B

CAS.NO:120814-48-4

Synonyms:(PRO7)-NEUROKININ B;ASP-MET-HIS-ASP-PHE-PHE-PRO-GLY-LEU-MET-NH2;H-ASP-MET-HIS-ASP-PHE-PHE-PRO-GLY-LEU-MET-NH2;H2N-ASP-MET-HIS-ASP-PHE-PHE-PRO-GLY-LEU-MET-NH2;L-Asp-L-Met-L-His-L-Asp-L-Phe-L-Phe-L-Pro-Gly-L-Leu-L-Met-NH2

Molecular Formula:C₅₅H₇₇N₁₃O₁₄S₂

Molecular Weight:1208.41000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:476.10000

Exact Mass:1207.52000

LogP:2.71840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (PRO7)-NEUROKININ B chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Asp-L-Met-L-His-L-Asp-L-Phe-L-Phe-L-Pro-Gly-L-Leu-L-Met-NH2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,H2N-ASP-MET-HIS-ASP-PHE-PHE-PRO-GLY-LEU-MET-NH2 Use and application,(PRO7)-NEUROKININ B technical grade,usp/ep/jp grade.

Related News: Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. (Pro7)-Neurokinin B manufacturer DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. (Pro7)-Neurokinin B supplier DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. (Pro7)-Neurokinin B vendor Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. (Pro7)-Neurokinin B factory Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.